menubarKalispell Regional Healthcare

Kalispell Regional Healthcare

Closed Studies

KRH Default

Cancer

GENUINE TRIAL
A phase III randomized study to assess the efficacy and safety of ublituximab in combination with ibrutinib compared to ibrutinib alone, in patients with previously treated high-risk chronic lymphocytic leukemia.
Principal investigator: Elise Anderes

JANUS 1
A randomized, double-blind, phase III study of the JAK1/2 inhibitor ruxolitinib or placebo in combination with capecitabine in subjects with advanced or metastatic adenocarcinoma of the pancreas who have failed or are intolerant to first-line chemotherapy.
Principal investigator: Ryan Roop

SIGNATURE
Modular phase II study to link targeted therapy to patients with pathway activated tumors: module 3 - MEK162 for patients with RAS/RAF/MEK activated tumors.
Principal investigator: Ryan Roop

TGTX-LAB-001
Screening protocol to determine high-risk cytogenetic features in patients with previously-treated chronic lymphocytic leukemia that may be eligible for TG Therapeutics trial UTX-IB-301.
Principal investigator: Elise Anderes

Cardiology

EUCLID
A randomized, double-blind, parallel-group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established peripheral artery disease.
Principal investigator: Robert Mitchell

EVITA
Evaluation of varenicline (Champix) in smoking cessation for patients post-acute coronary syndrome.
Principal investigator: Eve Gillespie

GEMINI ACS 1
A randomized, double-blind, double-dummy, active-controlled, parallel-group, multicenter study to compare the safety of rivaroxaban versus acetylsalicylic acid in addition to either clopidogrel or ticagrelor therapy in subjects with acute coronary syndrome.
Principal investigator: Eve Gillespie

GLORIA-AF
Global registry on long-term oral antithrombotic treatment in patients with atrial fibrillation (phase II/III).
Principal investigator: Eve Gillespie

PIONEER-AF-PCI
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention.
Principal investigator: Eve Gillespie

PRECISION
Prospective randomized evaluation of celecoxib integrated safety vs. Ibuprofen or naproxen.
Principal investigator: Eve Gillespie

PREPARE
Protocol 28431754PRD0001.
Principal investigator: Eve Gillespie

REVEAL AF
Reveal AF is a prospective, single-arm, open-label, multicenter, post-market interventional clinical study to determine, via continuous monitoring with the Reveal XT implantable cardiac monitor or newer approved version, the incidence of atrial fibrillation (AF) in patients suspected to be at high risk for having AF and to understand how physicians manage these patients once AF has been detected.
Principal investigator: Eve Gillespie

SPIRE 1
Studies of PCSK9 inhibition and the reduction of vascular events.
Principal investigator: Eve Gillespie

SPIRE 2
Studies of PCSK9 inhibition and the reduction of vascular events.
Principal investigator: Eve Gillespie

Endocrinology

DEVOTE
A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with Type 2 diabetes at high risk of cardiovascular events.
Principal investigator: Jose de Souza

EBBINGHAUS
Evaluating PCSK9 binding antibody influence on cognitive health in high cardiovascular risk subjects.
Principal investigator: Jose de Souza

FOURIER
A double-blind, randomized, placebo-controlled, multicenter study assessing the impact of additional LDL cholesterol reduction on major cardiovascular events when evolocumab (AMG 145) is used in combination with statin therapy in patients with clinically evident cardiovascular disease.
Principal investigator: Jose de Souza

NALTREXONE BUPROPION
A multicenter, randomized, double-blind, placebo-controlled, phase IV study to assess the effect of naltrexone hydrochloride and bupropion hydrochloride extended release combination on the occurrence of major adverse cardiovascular events in overweight and obese subjects with cardiovascular disease.
Principal investigator: Jose de Souza

NN9535-4191
Dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with Type 2 diabetes.
Principal investigator: Jose de Souza

Pain Management and Rheumatology Outreach

SUNBURST
Success using neuromodulation with burst (Sunburst) study.
Principal investigator: Camden Kneeland

Rheumatology

1297.2
Efficacy, safety and immunogenicity of BI 695501 versus adalimumab in patients with active rheumatoid arthritis: a randomized, double-blind, parallel-arm, multiple-dose, active comparator trial.
Principal investigator: Roger Diegel

1297.3
Long-term assessment of safety, efficacy, pharmacokinetics and immunogenicity of BI 695501 in patients with rheumatoid arthritis: an open-label extension trial for patients who have completed trial 1297.2 and are eligible for long-term treatment with adalimumab.
Principal investigator: Roger Diegel

CELGENE 003
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of apremilast (CC-10004) in subjects with active psoriatic arthritis.
Principal investigator: Roger Diegel

CELGENE 006
A phase IIIb, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast (CC-10004) monotherapy in subjects with active psoriatic arthritis.
Principal investigator: Roger Diegel

ENTRACTE
A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab in comparison with etanercept on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis.
Principal investigator: Roger Diegel

Other

BIO WELLNESS
Principal investigator: Jon Johnson

DEVELOPMENT AND VALIDATION THE REASONS TO EXERCISE SCALE
Principal investigator: Brad Roy

IDENTIFICATION OF THOSE WITH POSSIBLE CELIAC DISEASE
Evidence for use of health assessment questionnaire/tool for earlier identification of those with possible celiac disease.
Principal investigator: Kelly Walker

NAS
Improve the accuracy of the Finnegan scoring system for neonatal abstinence syndrome.
Principal investigator: Mark Kaneta

PIP
The effect of complementary and alternative medicine on stress biomarkers.
Principal investigator: DonnaLee Forbes

RN SURVEY
RN survey with job satisfaction – R and the optional JSS magnet module.
Principal investigator: Kari Hagler

TRIALNET
TrialNet natural history study of the development of Type 1 diabetes.
Principal investigator: Virginia Lewis